

Miren Altuna-Azkargorta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2255265/publications.pdf>

Version: 2024-02-01

33
papers

550
citations

840776

11
h-index

752698

20
g-index

36
all docs

36
docs citations

36
times ranked

559
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020, 395, 1988-1997.	13.7	164
2	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	5.9	47
3	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	3.7	44
4	Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. <i>Journal of Clinical Medicine</i> , 2021, 10, 2776.	2.4	43
5	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	12.8	33
6	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	9.0	32
7	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	8.0	32
8	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	1.9	30
9	Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12047.	2.4	25
10	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	10.8	21
11	The $A\beta_{42}/A\beta_{40}$ ratio in CSF is more strongly associated to tau markers and clinical progression than $A\beta_{42}$ alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	6.2	18
12	Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4307.	4.1	14
13	Sleep Disorders in Adults with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3012.	2.4	12
14	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	2.4	7
15	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	5.3	7
16	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	6.2	6
17	Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review. <i>Medicina (Lithuania)</i> , 2022, 58, 473.	2.0	6
18	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020, 10, 13755.	3.3	4

#	ARTICLE	IF	CITATIONS
19	DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. <i>Biomedicines</i> , 2022, 10, 1380.	3.2	2
20	Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 838412.	2.8	1
21	Progressive cognitive impairment and familial spastic paraparesis due to PRESENILIN 1 mutation: anatomoclinical characterization. <i>Journal of Neurology</i> , 2022, , 1.	3.6	1
22	O2â€œ09â€œ01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P558.	0.8	0
23	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e041255.	0.8	0
24	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020, 16, e041500.	0.8	0
25	The effect of APOE É4 in Alzheimer's disease biomarkers in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e042889.	0.8	0
26	1 Hâ€œMRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.8	0
27	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020, 16, e043491.	0.8	0
28	Lateâ€œonset epileptic seizures in adults with Down syndrome are linked to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
29	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
30	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
31	Neuropsychological correlates of plasma NfL in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
32	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and populationâ€œbased study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
33	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0